Novartis Oncology and AliHealth Announce Strategic Collaboration to Build an Integrated Digital Healthcare Ecosystem for Cancer Patients

Original Title: On the Ground at the CIIE | Novartis Oncology and AliHealth Partner to Build a Closed-Loop for Digital Healthcare Innovation Source: Yiou.com

EO Intelligence Health, November 7 — Today, Novartis Oncology and AliHealth announced a strategic partnership at the China International Import Expo (CIIE). Centered on patients, the collaboration will leverage Novartis Oncology’s strengths in precision oncology and AliHealth’s digital healthcare platform to empower digital transformation, integrate resources, and create an innovative “Internet + physicians + pharmacists + patients + charity” digital healthcare model, thereby providing comprehensive digital health solutions for cancer patients.

In the context of normalized epidemic prevention and control, cancer patients face substantial unmet needs in traditional healthcare settings across four key areas: prescription accessibility, medication availability, treatment adherence, and drug payment coverage.

“Leveraging AliHealth’s leading digital technology and our expertise in oncology, we are committed to delivering exceptional value to patients and healthcare professionals by providing a one-stop service for cancer patients that covers online prescriptions, online medication purchases, affordability solutions, and process compliance. We will work together to integrate patients, physicians, pharmacists, and charitable organizations to offer comprehensive digital health solutions for cancer patients,” said Alexandre Gibim, General Manager of Novartis Oncology China. “Novartis Oncology is increasing its investment in digital innovation through its strategic partnership with AliHealth.”

“When confronted with a serious illness such as cancer, every family faces immense pressure in terms of treatment, emotional well-being, and finances.” Zhu Shunyan, Chairman and CEO of AliHealth, stated, “Novartis Oncology is an expert in the field of precision oncology and continuously explores innovative ways to serve patients through philanthropy and technology. This aligns perfectly with AliHealth’s goals and philosophy. We hope that our strategic partnership will leverage digital technology and the power of philanthropy to enable patients to access high-quality medical services more conveniently, improve their quality of life, alleviate the burden of disease, and benefit more cancer patients.”

According to Zhu Shunyan’s on-site introduction, subsequent collaboration between the two parties will specifically focus on patient assistance and patient education. By partnering with public welfare and charitable organizations, the initiative will integrate resources from physicians, pharmacists, and charitable entities to address application scenarios such as follow-up visit medication purchases, Patient Assistance Programs (PAP), and medication counseling. Leveraging digitalization, it aims to reengineer disease management processes and provide patients with comprehensive digital health solutions.

At that time, patients will be able to easily complete the entire process of online follow-up consultations, medical care, and medication purchases without leaving their homes, thereby improving prescription availability and drug accessibility. Professional clinical pharmacists on the internet hospital platform can also provide guidance and answers to patients, offering professional online medication consultation services to help resolve medication-related issues and enhance medication adherence.

Meanwhile, the collaboration will integrate high-quality medical resources by attracting a large number of physicians to join the internet hospital, thereby breaking through geographical barriers via online diagnosis, treatment, and consultations. This initiative aims to decentralize premium medical resources and provide healthcare services to oncology patients across China. Furthermore, both parties will explore patient protection solutions, offering innovative payment methods and diverse pharmaceutical payment options.